COX-2 Expression in Ovarian Cancer: an Updated Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 21

PMID 29152148

Citations 12

Authors

Haiming Sun

Xuelong Zhang

Donglin Sun

Xueyuan Jia

Lidan Xu

Yuandong Qiao

Yan Jin

Affiliations

Soon will be listed here.

Abstract

The prognostic role of COX-2 expression in ovarian cancer patients has been studied for years, while results remain controversial. Thus we performed a meta-analysis to evaluate the prognostic impact of COX-2 expression on survival of ovarian cancer patients. The databases PubMed, Embase and CNKI were searched. Summary hazard ratio (HR) and 95% confidence intervals (CIs) were calculated to analyze the correlations between COX-2 expression and overall survival (OS), and disease-free survival (DFS). A total of 1,867 patients from 18 studies were enrolled in the final analysis. The results showed that patients with higher COX-2 expression had a poor OS (HR: 1.48; 95% CI: 1.19-1.85) and DFS (HR: 1.81, 95% CI: 1.28-2.55). Subgroup analysis showed that there had significant associations between COX-2 expression and survival rate in most of the subgroups. Furthermore, there were significant associations between COX-2 expression and several clinical parameters such as FIGO stage, histological type and age. These results showed the patients with higher COX-2 expression had a significantly poorer survival rate, COX-2 expression had the potential to be a prognostic marker of ovarian cancer.

Citing Articles

Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.

Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B J Inflamm Res. 2025; 18:895-909.

PMID: 39867950 PMC: 11762012. DOI: 10.2147/JIR.S503479.

Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer.

Hillmann J, Maass N, Bauerschlag D, Florkemeier I BMC Med. 2025; 23(1):10.

PMID: 39762846 PMC: 11706140. DOI: 10.1186/s12916-024-03826-w.

The deregulation of arachidonic acid metabolism in ovarian cancer.

Xia Q, Gao W, Yang J, Xing Z, Ji Z Front Oncol. 2024; 14:1381894.

PMID: 38764576 PMC: 11100328. DOI: 10.3389/fonc.2024.1381894.

Immune pathway through endometriosis to ovarian cancer.

Santos Calmon M, Bueno Lemos F, Silva Luz M, Rocha Pinheiro S, de Oliveira Silva L, Lima Correa Santos G World J Clin Oncol. 2024; 15(4):496-522.

PMID: 38689629 PMC: 11056862. DOI: 10.5306/wjco.v15.i4.496.

Targeting inflammation as cancer therapy.

Wang M, Chen S, He X, Yuan Y, Wei X J Hematol Oncol. 2024; 17(1):13.

PMID: 38520006 PMC: 10960486. DOI: 10.1186/s13045-024-01528-7.

References

Wang M, He Y, Shi L, Shi C . Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011; 32(2):171-7. View

Lou W, Shen K, Zhang Y, Lang J . [Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2004; 39(8):529-32. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Greenhough A, Smartt H, Moore A, Roberts H, Williams A, Paraskeva C . The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009; 30(3):377-86. DOI: 10.1093/carcin/bgp014. View

Lee J, Park J, Suh J, Nam K, Choe J, Jung H . Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol. 2012; 46(3):237-45. PMC: 3479766. DOI: 10.4132/KoreanJPathol.2012.46.3.237. View

Kang C, Kim H, Kim H, Lee W . Cyclooxygenase-2 (COX-2) expression in solid pseudopapillary tumor of the pancreas: a pilot study. Pancreas. 2010; 40(1):159-61. DOI: 10.1097/MPA.0b013e3181f74ca5. View

Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M . Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002; 160(3):893-903. PMC: 1867167. DOI: 10.1016/S0002-9440(10)64912-7. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

10.

Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52(1):23-47. DOI: 10.3322/canjclin.52.1.23. View

11.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

12.

Chen J, Wu F, Pei H, Gu W, Ning Z, Shao Y . Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer. Oncol Lett. 2015; 10(4):2197-2203. PMC: 4579898. DOI: 10.3892/ol.2015.3624. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P . Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2009; 126(2):382-94. DOI: 10.1002/ijc.24757. View

15.

Barisik N, Keser S, Gul A, Sensu S, Onak Kandemir N, Kucuk H . The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast. Med Oncol. 2010; 28(3):703-8. DOI: 10.1007/s12032-010-9503-6. View

16.

Ferrandina G, Lauriola L, Zannoni G, Fagotti A, Fanfani F, Legge F . Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol. 2002; 13(8):1205-11. DOI: 10.1093/annonc/mdf207. View

17.

Ferrero A, Dompe D, Ravarino N, Ramella A, Fuso L, Maggiorotto F . Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study. Gynecol Oncol. 2011; 123(2):301-7. DOI: 10.1016/j.ygyno.2011.07.026. View

18.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

19.

Ozuysal S, Bilgin T, Ozgur T, Celik N, Evrensel T . Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival. Eur J Gynaecol Oncol. 2010; 30(6):640-5. View

20.

Magnowska M, Zaborowski M, Surowiak P, Nowak-Markwitz E, Zabel M, Spaczynski M . COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis. Ginekol Pol. 2014; 85(5):335-41. DOI: 10.17772/gp/1733. View